Browse
Submit Data
Databases
API
Help

Dataset Information

40 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Irish Thoracic Society Annual Scientific Meeting 2020.

ABSTRACT:

SUBMITTER:

PROVIDER: S-EPMC7788179 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Irish Thoracic Society Annual Scientific Meeting 2022 Abstract Book 1 - 3 December 2022, Naas, Ireland.

Project description: Not available

| S-EPMC9707199 | biostudies-literature

Proceedings of the Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2020.

Project description: Not available

| S-EPMC8009688 | biostudies-literature

36th Annual Scientific Meeting of the Canadian Pain Society: Abstracts

Project description:A full-text version of the abstracts to be presented at the 36th Annual Scientific Meeting of the Canadian Pain Society is published online only. To view the full-text abstracts, go to www.pulsus.com

| S-EPMC4447163 | biostudies-literature

Proceedings of the Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2019

Project description: Not available

| S-EPMC7313110 | biostudies-literature

Proceedings of the Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2018

Project description: Not available

| S-EPMC6399812 | biostudies-literature

Abstracts for the 2023 Transplantation Society of Australia and New Zealand Annual Scientific Meeting

Project description: Not available

| S-EPMC10750682 | biostudies-literature

American Society of Hematology 2015 Annual Meeting.

Project description:The annual meeting of the American Society of Hematology drew 25,000 attendees for the presentation of 5,633 abstracts. We review key sessions focusing on newer agents and their efficacy in high-risk leukemia and multiple myeloma populations.

| S-EPMC4745640 | biostudies-literature

Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020.

Project description:Treatment of multiple myeloma (MM) has advanced dramatically in the past two decades. However, under the conditions of the COVID-19 pandemic, treatment strategies have been modified accordingly. Numerous novel agents, updated trials, and major advances in myeloma have been reported in the American Society of Hematology 2020 annual meeting, either for transplant-eligible or ineligible patients. Hot topics such as the significance of autologous stem cell transplantation (ASCT), development of novel agents, and chimeric antigen receptor-T (CAR-T) cells have been widely discussed. The triplet regimen bortezomib, lenalidomide, and dexamethasone (VRd) is recommended as the standard first-line treatment, and the addition of a fourth drug improves efficacy and survival. The value of ASCT remains undoubtful, even in the era of quadruplet induction. Dual-drug maintenance, including proteasome inhibitors and immunomodulatory drugs, overcomes unfavorable outcomes in high-risk patients. For relapsed/refractory myeloma (RRMM) patients, novel agents such as selinexor and venetoclax are superior. CAR-T cells and other cell-surface-targeted therapies also appear promising.

| S-EPMC8579022 | biostudies-literature

Abstracts of the 12th BOMSS Annual Scientific Meeting.

Project description: Not available

| S-EPMC8541806 | biostudies-literature

Abstracts for the 2021 TSANZ Annual Scientific Meeting

Project description: Not available

| S-EPMC8109145 | biostudies-literature